Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN
暂无分享,去创建一个
R. Russell | E. Miele | J. Fell | D. Turner | S. Koletzko | R. Shaoul | M. Aloi | J. Bronský | G. Veereman | I. Hojsak | S. Buderus | Liron Birimberg-Schwartz
[1] M. Aloi,et al. Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management , 2017, Pediatric Drugs.
[2] M. Mearin,et al. Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry , 2015, Inflammatory bowel diseases.
[3] J. Kelsen,et al. Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger , 2014, Journal of pediatric gastroenterology and nutrition.
[4] A. Griffiths,et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. , 2014, Journal of Crohn's & colitis.
[5] D. Schwartz,et al. Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis–Predominant IBD , 2014, Journal of pediatric gastroenterology and nutrition.
[6] S. Saxena,et al. The Role of Thiopurines in Reducing the Need for Surgical Resection in Crohn's Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.
[7] G. Veres,et al. ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.
[8] J. Tomaino,et al. Analysis of current treatments used in clinical practice in a pediatric summer camp population for children with inflammatory bowel disease , 2012, Inflammatory bowel diseases.
[9] David C. Wilson,et al. Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines , 2012, Journal of pediatric gastroenterology and nutrition.
[10] B. Abraham,et al. Inflammatory bowel disease characteristics in Hispanic children in Texas , 2012, Inflammatory bowel diseases.
[11] O. Goulet,et al. The efficacy of exclusive nutritional therapy in paediatric Crohn’s disease, comparing fractionated oral vs. continuous enteral feeding , 2011, Alimentary pharmacology & therapeutics.
[12] David C Wilson,et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.
[13] S. Saxena,et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[14] A. Akobeng,et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[15] David C. Wilson,et al. Consensus for Managing Acute Severe Ulcerative Colitis in Children: A Systematic Review and Joint Statement From ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN , 2011, The American Journal of Gastroenterology.
[16] C. Deslandres,et al. Methotrexate in the treatment of inflammatory bowel disease: An 8‐year retrospective study in a Canadian pediatric IBD center , 2009, Inflammatory bowel diseases.
[17] H. Uhlig,et al. Frequency of indeterminate colitis in children and adults with IBD - a metaanalysis. , 2009, Journal of Crohn's & colitis.
[18] R. Russell,et al. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission , 2009, Alimentary pharmacology & therapeutics.
[19] C. Romano,et al. Indeterminate Colitis: A Distinctive Clinical Pattern of Inflammatory Bowel Disease in Children , 2008, Pediatrics.
[20] P. Munkholm,et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] P. Davies,et al. Predicting the Need for Azathioprine at First Presentation in Children With Inflammatory Bowel Disease , 2008, Journal of pediatric gastroenterology and nutrition.
[22] B. Koletzko,et al. ESPGHAN and ESPEN Guidelines Paediatric Parenteral Nutrition - Annex: List of Products , 2005, Journal of pediatric gastroenterology and nutrition.
[23] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[24] J. Hugot,et al. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. , 2005, Journal of pediatric gastroenterology and nutrition.
[25] S. Targan,et al. Infliximab in the treatment of medically refractory indeterminate colitis , 2003, Alimentary pharmacology & therapeutics.
[26] R. Modigliani,et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open‐label multicentre study , 2003, Alimentary pharmacology & therapeutics.
[27] J. Avilés,et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. , 2001, Scandinavian journal of gastroenterology.